Medical Science News

RSS

Top-line results from Probiodrug's PQ912 Phase 1 SAD, MAD study for Alzheimer's disease

Probiodrug AG, a biotech company developing products for the treatment of neurodegenerative and inflammatory diseases, with a particular focus on Alzheimer's disease (AD), today announced top-line results of its Phase 1 single (SAD) and multiple ascending dose (MAD) study of PQ912 in healthy volunteers.

14 Nov 2011

Global demand to join pioneering adult stem cell study to treat ALS

BrainStorm Cell Therapeutics Inc., an innovative developer of adult stem cell technologies and CNS therapeutics, today announced that patients from across the globe are demanding to be included in the pioneering clinical study started earlier this year at Jerusalem's Hadassah University Medical Center.

14 Nov 2011

New Allen Mouse Brain Connectivity Atlas

The Allen Institute for Brain Science announced today the launch of a new brain atlas resource and updates to four existing resources, all publicly available online to accelerate brain research around the globe.

14 Nov 2011

New insight into how the human brain learns and remembers

New research released today provides insight into one of neuroscience's most intriguing mysteries: how the human brain learns and remembers. These studies - involving topics as diverse as musical memory, "change blindness," and attention deficit hyperactivity disorder (ADHD) - illustrate the profound influence that specific changes in either the brain's structure, function, or both, can have on human behavior.

14 Nov 2011

Luminescent upconversion nanocrystals can detect cancer cells

Upconversion emission materials are ideal for bioimaging due to its effectiveness as contrast agents for the detection of cancer cells, more so when the background emission of non-cancerous tissues can be minimised. These materials could be used as biomarkers for luminescent labeling of cancerous cells. Opaque tissues can be turned into glassy, transparent substances by using these biomarkers which rely on near-infrared excitation.

14 Nov 2011

Occupational chemical exposure raises for Parkinson's

A new research report contributes to the increasing evidence that repeated occupational exposure to certain chemical solvents raises the risk for Parkinson's disease. Researchers analyzed the occupational histories of twins in which one of the pair developed the neurodegenerative disorder, and assessed that twin's likelihood of exposure to six chemicals previously linked to Parkinson's.

14 Nov 2011

Scientists discover molecular basis for tamoxifen resistance and potential way to defeat it

In the last three decades, thousands of women with breast cancer have taken the drug tamoxifen, only to discover that the therapy doesn't work, either because their tumors do not respond to the treatment at all, or because they develop resistance to it over time. Now researchers at the University of California, San Francisco (UCSF) have discovered the molecular basis for tamoxifen resistance and found a potential way to defeat it.

14 Nov 2011

Scientists create new phenotypic cancer drug screening platform

Researchers have created a new phenotypic screening platform that better predicts success of drugs developed to prevent blood vessel tumor growth when moving out of the lab and onto actual tumors.

14 Nov 2011

Scientists identify factors that lead to concomitant tumor resistance

Scientists are another step closer to understanding what drives tumor metastasis, as laboratory models suggest there are factors inside tumors that can slow their own growth.

14 Nov 2011

Next-generation drugs may prevent skin lesions in BRAF mutation-positive melanoma

Findings from preclinical studies in a skin cancer model showed that next-generation BRAF inhibitors used alone, or first-generation BRAF inhibitors used in combination with an epidermal growth factor receptor inhibitor, may have the potential to prevent drug-induced skin lesions in BRAF mutation-positive patients treated for melanoma.

14 Nov 2011

ZIOPHARM announces darinaparsin preclinical data on prostate cancer

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today that results from preclinical studies of darinaparsin (Zinapar or ZIO-101), a novel organic arsenic, in prostate cancer were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place November 12-16 in San Francisco.

14 Nov 2011

Combination of REGN910 and aflibercept inhibits tumor angiogenesis in animal models

Combining the investigational agents REGN910 and aflibercept yielded statistically significant improvements in antitumor effects in animal models compared with either agent alone, according to results presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, held Nov. 12-16, 2011.

14 Nov 2011

Penn-led team develops microelectronic device to map brain activity

A team of researchers co-led by the University of Pennsylvania has developed and tested a new high-resolution, ultra-thin device capable of recording brain activity from the cortical surface without having to use penetrating electrodes.

14 Nov 2011

Amplification of ALK gene may drive rapid breast cancer metastasis

Amplification of anaplastic lymphoma kinase, which has been reported in other cancers such as non-small cell lung cancers, may be a primary driver of the rapid metastasis that patients with inflammatory breast cancer experience.

14 Nov 2011

Researchers show how ER-positive breast cancer tumors become resistant to tamoxifen

Researchers have shown how estrogen receptor-positive breast cancer tumors become resistant to tamoxifen, the only approved hormonal therapy for premenopausal patients with this type of breast cancer.

14 Nov 2011

Researchers identify new cancer drug discovery approach

Researchers at the University of California, San Diego School of Medicine and the UC San Diego Moores Cancer Center have identified a new drug discovery approach enabling the destruction of the most highly proliferative tumors.

14 Nov 2011

Patients with KRAS mutant NSCLC should respond well to antifolates

Patients with non-small cell lung cancer who have mutations in the KRAS gene should respond well to the antifolate class of drugs, according to results of a recent study conducted by Quintiles comparing human lung cancer cell lines and patients.

14 Nov 2011

Novel gene mutation may increase risk of inherited and sporadic cases of MM

A major international study has identified a novel gene mutation that appears to increase the risk of both inherited and sporadic cases of malignant melanoma, the most deadly form of skin cancer.

14 Nov 2011

Researchers retrace evolution of unusual bacterial infection

Researchers at Harvard Medical School and Children's Hospital Boston have retraced the evolution of an unusual bacterial infection as it spread among cystic fibrosis patients by sequencing scores of samples collected during the outbreak, since contained.

14 Nov 2011

Low levels of vitamin C associated with worse outcomes for heart failure patients

Low levels of vitamin C were associated with higher levels of high sensitivity C-Reactive protein (hsCRP) and shorter intervals without major cardiac issues or death for heart failure patients, in research presented at the American Heart Association's Scientific Sessions 2011.

14 Nov 2011